Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The field is moving toward inflammation models
What We Know About GLP-1s and Addiction Here the signal is surprisingly strong but still preliminary
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
VYKAT XR is indicated for patients aged 4 years and older with PWS, a disorder characterized by low muscle tone, short stature, and cognitive and developmental difficulties
US$ 25.49
US$ 27.60
US$ 26.31
US$ 28.68
US$ 22.22
